Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ideaya Biosciences Inc. maintains 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct examiners and 2 distinct art units, showing a diversified prosecution landscape for the company's current filings. This diversification suggests that the company is pursuing multiple distinct technological paths within the broader Biotechnology & Pharmaceuticals field. Navigating 2 different art units requires a flexible approach to claim drafting to meet the specific requirements of each distinct examination group.
HUTTER, GILLIAN A is the busiest examiner for the portfolio, currently managing 1 pending office action. This distribution indicates that each pending action is being handled by a different examiner in a different art unit, requiring the company to navigate multiple examination styles. With the 1 pending office action assigned to HUTTER, GILLIAN A, the company must balance this specific interaction against other pending matters, as the success of the portfolio is subject to the varied perspectives of 2 distinct examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTTER, GILLIAN A | 1 | 54.5% | +46.2% |
| YOO, SUN JAE | 1 | 71.1% | +0.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18501729 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | HUTTER, GILLIAN A | 8d overdue |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18501729 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | HUTTER, GILLIAN A | 1625 | §103DP | Non-Final OA | 8d overdue | Pending | Nov 03, 2023 |
| 17420833 | TREATMENT OF CANCER HAVING GNAQ OR GNA11 GENETIC MUTATIONS WITH PROTEIN KINASE C INHIBITORS | YOO, SUN JAE | 1621 | — | Non-Final OA | — | Pending | Jul 06, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial